陕西医学杂志2024，Vol.53Issue(6)：858-861,4.DOI:10.3969/j.issn.1000-7377.2024.06.029
髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展
Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma
摘要
Abstract
Multiple myeloma(MM)is an incurable plasma B-cell malignancy.Treatment options include combi-nation chemotherapy and autologous stem cell transplantation.However,the role of current drugs in controlling tumor progression and prolonging remission time of MM is limited,and not all patients are able to receive autologous stem cell transplantation.The overexpression of Bcl-2 family proteins,particularly myeloid cell leukemia 1(MCL-1),plays a critical role in the pathogenesis of MM.The overexpression of MCL-1 is associated with drug resistance and overall poor prognosis in MM patients.Thus,inhibition of MCL-1 protein is a therapeutic strategy to kill myeloma cells.Over the past decade,significant progress has been made in the development of selective MCL-1 inhibitors.This article reviews the research progress of MCL-1 inhibitors in the treatment of MM.关键词
多发性骨髓瘤/髓细胞白血病1抑制剂/B细胞淋巴瘤2/耐药/自体干细胞移植Key words
Multiple myeloma/Myeloid cell leukemia 1 inhibitor/B-cell lymphoma 2/Drug resistance/Autolo-gous stem cell transplantation分类
医药卫生引用本文复制引用
滕远,李莉娟,张连生..髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展[J].陕西医学杂志,2024,53(6):858-861,4.基金项目
国家自然科学基金资助项目(82360029) （82360029）
